Open AccessP965: FOLLOW‐UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG‐1211)
Author(s) -
Usmani S.,
Hoering A.,
Ailawadhi S.,
Sexton R.,
Lipe B.,
Valent J.,
Rosenzweig M.,
Zonder J.,
Dhodapkar M.,
Callander N.,
Zimmerman T.,
Voorhees P.,
Durie B.,
Rajkumar S. V.,
Richardson P.,
Orlowski R.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846728.05693.f8
Subject(s) - lenalidomide , bortezomib , multiple myeloma , medicine , clinical endpoint , autologous stem cell transplantation , oncology , progression free survival , transplantation , dexamethasone , adverse effect , phases of clinical research , gastroenterology , surgery , randomized controlled trial , clinical trial , chemotherapy